Page 26 - Bio Developments News Today

UCB recently announced the European Commission approval for Bimzelx (bimekizumab), its humanized monoclonal IgG1 antibody.

Unquestionably, the buzzword of 2023 is artificial intelligence (AI). From ChatGPT-4 preparing to revolutionize online research to IBM’s project debater engaging humans in live debates, it’s clear that we stand at the dawn of a new era of assistive and generative technology.

SMi Systems, a company specializing in single molecule imaging and quantification technologies, has disclosed a £6m seed funding round to develop the utility of a novel multi-omic platform for in vitro diagnosis and biomedical research.

Poolbeg Pharma, a clinical-stage biopharma company focusing on infectious and other prevalent diseases with high unmet medical needs, has announced an update to its oral vaccine programme.

Sphere Fluidics, a company developing single cell analysis systems, has announced that Biosyntia, a biotech company focused on synthetic biology and metabolic engineering, has adopted its Pico-Mine platform within its workflows.

Mimetas, a biotech company developing human organ-on-a-chip tissue models and products for drug development, has expanded its ongoing partnership with global pharmaceutical company Astellas, to include automation and application support.

Providence Therapeutics, a biopharmaceutical company developing mRNA vaccines and therapeutics, has announced its partnership with University Health Network (UHN).

A-Alpha Bio, a synthetic biology and machine learning company, has announced its collaboration with Gilead that aims to advance the design of human immunodeficiency virus (HIV) therapies.

Katherine Vega Stultz is the CEO and president of Ocelot Bio, a clinical-stage biotech company focused on the development of therapeutics to treat complications of end-stage liver disease.

Axol Bioscience Ltd, a pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.